Real Time Case - Customer Support FAQ

Welcome to the Real Time Case Support FAQ! Here you'll find answers to common questions about our application and how to contact us for further assistance.
  • How do I register for Real Time Case?
    • Register for access through the application. After submission, your registration will be reviewed within 48 hours.

  • How will I know if my registration is approved?
    • You will receive an email notification confirming your approval.

  • What can I do after logging in?
    • After logging in, you can:
      • View all available cases in the Cases Dashboard.
      • Access cases you've created.
      • Favorite cases for quick access.

  • How do I interact with cases?
    • Click on a case card to view detailed information.
    • Favorite a case by selecting the icon in the top-right corner.
    • Use the "View Comments" option to see existing comments, add your own comments, or reply to others.

  • How do I create a new case?
    • From the Cases Dashboard:
      • Click "Create New Case" in the footer.
      • Enter details manually or use speech-to-text functionality.
      • Review the parsed detailed clinical information.
      • Ensure all data, including Tumor Type, Histology, Stage, and Lines of Therapy are accurate
      • You can upload up to a maximum of 2 photos
      • Click "Create" to submit your case.

  • How do I comment on case?
    • From the Cases Dashboard:
      • Select a case from the dashboard
      • View the case details
      • At the bottom of the case there is a count of the current number of comments
      • You can select to View or comment
      • This will take you to a new page to view all the comments and replies
      • Select the New Comment icon, this will open a dialog box to submit a new comment
        • To reply to a comment, select the comment and select the comment icon and submit

  • Can you provide examples of optimal case descriptions?
    • Example Case 1:
      55 yo Caucasian woman, never smoker, ECOG PS 0, originally presented with jaundice and right upper quadrant pain. CT scan showed a 10 cm left hepatic lobe mass, with a biopsy showing poorly differentiated adenocarcinoma. The patient underwent a partial hepatectomy and cholecystectomy, with pathology showing invasive moderately differentiated adenocarcinoma involving the liver parenchyma, with the tumor measuring 10.2 cm and 0/9 lymph nodes involved for pT2N0. Next generation sequencing showed an FGFR2-BICC1 fusion and BAP1 mutation. The patient received 6 cycles of adjuvant gemcitabine and capecitabine and went on surveillance. One year later, a CT scan demonstrated a 4 cm mass in the right lobe of the liver. The patient was started on gemcitabine, cisplatin, and durvalumab with a partial response in the liver. However, on the following restaging scan, a suspicious pelvic lesion was seen on scans which also was FDG avid on PET scan. A biopsy of the pelvic lesion confirmed moderately differentiated adenocarcinoma consistent with metastatic cholangiocarcinoma. The patient was switched to pemigatinib. This was poorly tolerated with diarrhea, fatigue, and nail changes requiring dose reduction, but first restaging scan showed a partial response in the liver lesion and stable disease of the pelvis. A restaging scan showed 2 new liver lesions. ECOG performance status is still 0. A blood-based liquid biopsy is sent, with no actionable mutations.
    • Example Case 2:
      66 yo Caucasian man, never smoker, ECOG PS 1, originally presented with melena and hematochezia. The patient had a colonoscopy that showed a 4 cm mass in the ascending colon. Next-generation sequencing showed no targetable mutations, tumor mutational burden of 7 mut/Mb, and microsatellite stability. CT scan followed showing four liver lesions thought to be metastases. The patient starts bevacizumab with FOLFOXIRI. Restaging scans show a partial response in the liver. After 8 cycles, the patient develops a massive headache and comes to the ER. CT head without contrast is unremarkable. The patient's blood pressure is found to be 220/120 (previously, it was well controlled only on lisinopril 20 mg). The patient is admitted for hypertensive urgency for one day requiring nicardipine drip, and he is discharged with a second antihypertensive agent of amlodipine 5 mg. The patient returns to clinic for his next cycle of therapy, with blood pressure normalized. Should the bevacizumab be continued?

  • How do I manage my profile?
    • Update your personal details and profile picture from the top-right navigation menu.

  • Where can I view my notifications?
    • Notifications can be viewed from the top-right navigation menu and include updates on case creations, new comments, and replies to your comments.

  • How do I contact support?
    For further assistance, please email our support team at: nem@realtimecase.com

Thank you for using Real Time Case!

Register or Login

Register to request access or login.